# US 2012/0251561 A1 · Administration of dendritic cells partially matured in vitro for the treatment of tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251561 A1
- Document ID: US20120251561A1
- Status: Published application
- Kind: A1
- Application number: 13/488,388
- Filed: 2012-06-04
- Published: 2012-10-04
- Earliest claimed: 2002-12-06
- Assignees: Northwest Biotherapeutics, Inc.
- Inventors: Marnix L. Bosch
- Web page: https://patentgrep.com/patent/US20120251561A1

## CPC

- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61K 2239/31: characterized by the route of administration
- A61K 2239/50: Colon
- C12N 2500/72: from bacteria
- C12N 2501/05: Adjuvants
- C12N 2501/24: Interferons [IFN]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides populations of cells comprising partially matured dendritic cells that can be used for administration individuals having a tumor. Partially matured dendritic cells, those contacted with a dendritic cell maturation agent for about 1 to about 10 hours, or more, efficiently take up and process tumor antigens in the area of the tumor site, complete maturation, and can subsequently migrate to the lymph nodes of a treated individual. Once in the lymph node the now fully mature antigen presenting dendritic cells secrete the appropriate cytokines (e.g., TNFα and IL-12) and contact T cells inducing a substantial anti-tumor immune response.

## Claims

### Claim 1

A method for producing an anti-tumor immune response comprising administration to an individual with a cancerous tumor a cell population comprising partially matured dendritic cells that have been induced to initiate maturation in vitro, wherein the partially matured dendritic cells take up and process antigen in vivo and are enabled to induce an anti-tumor immune response subsequent to administration to the individual.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the dendritic cells are obtained from skin, spleen, bone marrow, thymus, lymph nodes, umbilical cord blood, or peripheral blood.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the dendritic cells are obtained from the individual to be treated.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the dendritic cells are obtained from a healthy individual HLA-matched to the individual to be treated.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the dendritic cells are induced to partially mature in vitro in the presence of a dendritic cell maturation agent.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the dendritic cell maturation agent is Bacillus Calmette-Guerin (BCG), interferon γ (IFNγ), lipopolysaccharide (LPS), tumor necrosis factor α (TNFα), an imidazoquinoline compound, a synthetic double stranded polyribonucleotide, a agonist of a Toll-like receptor (TLR), a sequence of nucleic acids containing unmethylated CpG motifs known to induce the maturation of DC, or any combination thereof.

### Claim 7 (depends on 6)

The method according to claim 6, wherein BCG comprises whole BCG, cell wall constituents of BCG, BCG-derived lipoarabidomannans, or BCG components.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the BCG is heat-inactivated BCG or formalin-treated BCG.

### Claim 9 (depends on 6)

The method according to claim 6, wherein the effective amount of BCG is about 105 to 107 cfu per milliliter of tissue culture media and the effective amount of IFNγ is about 100 to about 1000 Units per milliliter of tissue culture media.

### Claim 10 (depends on 6)

The method according to claim 6, wherein the imidazoquinoline compound is an imidazoquinoline-4-amine compound.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the imidazoquinoline-4-amine compound is 4-amino-2-ethoxymethyl-α,α-dimethyl-1H-imidazol[4,5-c]quinolin-1-ethanol or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, or a derivative thereof.

### Claim 12 (depends on 6)

The method according to claim 6, wherein the synthetic double stranded polyribonucleotide is poly[I]:poly[C(12)U].

### Claim 13 (depends on 1)

The method according to claim 1, wherein the partially matured dendritic cells are administered directly into the cancerous tumor.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the partially matured dendritic cells are administered into a cancerous tumor bed subsequent to surgical removal or resection of the cancerous tumor.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the partially matured dendritic cells are administered to a tissue area surrounding the cancerous tumor.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the partially matured dendritic cells are administered into a lymph node directly draining a cancerous tumor area.

### Claim 17 (depends on 1)

The method according to claim 1, wherein partially matured dendritic cells are administered directly to a circulatory vessel duct that delivers blood or lymph to the cancerous tumor or a cancerous tumor afflicted organ.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the partially matured dendritic cells are administered into the circulatory system such that the cells are delivered to the cancerous tumor or cancerous tumor afflicted organ.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the partially matured dendritic cells are administered as an adjuvant to radiation therapy, chemotherapy, or combinations thereof.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the partially matured dendritic cells are administered prior to, simultaneous with, or subsequent to radiation therapy, chemotherapy, or combinations thereof.

### Claim 21

A composition comprising partially mature dendritic cells combined with a pharmaceutically acceptable carrier for in vivo administration, wherein the partially mature dendritic cells have been contacted in vitro with a dendritic cell maturation agent.

### Claim 22 (depends on 21)

The composition according to claim 21, wherein the partially mature dendritic cells demonstrate an up-regulation of co-stimulatory molecules CD80, CD86 and/or CD54 and retain the ability to uptake and process antigen.

### Claim 23 (depends on 21)

The composition according to claim 21, wherein the composition comprises about 102 to about 1010 partially matured dendritic cells.

### Claim 24 (depends on 21)

The composition according to claim 21, wherein the partially matured dendritic cells have been cryopreserved subsequent to partial maturation.

### Claim 25 (depends on 21)

The composition according to claim 21, wherein the partially matured dendritic cells have been isolated from a patient to whom they are to be administered.

### Claim 26 (depends on 21)

The composition according to claim 21, wherein the partially matured dendritic cells have been HLA matched to an individual to whom they are to be administered.

### Claim 27 (depends on 21)

The composition according to claim 21, wherein the partially matured dendritic cells are administered directly into the cancerous tumor.

### Claim 28 (depends on 21)

The composition according to claim 21, wherein the partially matured dendritic cells are administered into a cancerous tumor bed subsequent to surgical removal or resection of the cancerous tumor.

### Claim 29 (depends on 21)

The composition according to claim 21, wherein the partially matured dendritic cells are administered to a tissue area surrounding the cancerous tumor.

### Claim 30 (depends on 21)

The composition according to claim 21, wherein the partially matured dendritic cells are administered into a lymph node directly draining a cancerous tumor area.

### Claim 31 (depends on 21)

The composition according to claim 21, wherein partially matured dendritic cells are administered directly to a circulatory vessel duct that delivers blood or lymph to the cancerous tumor, cancerous tumor bed, or a cancerous tumor afflicted organ.

### Claim 32 (depends on 21)

The composition according to claim 21, wherein the partially matured dendritic cells are administered into the circulatory system such that the cells are delivered to the cancerous tumor, cancerous tumor bed, or cancerous tumor afflicted organ.
